The company is strengthening development and manufacturing offerings, says Anil Kane, global head of technical and scientific affairs for Thermo Fisher’s pharma services.
The agreements cover late-stage clinical supply of a monoclonal antibody targeting lymphoma and a small-molecule inhibitor being developed for actinic keratosis.
The Charles City facility will add 140,000 liters of capacity, while the company’s Milan site expansion is expected to be completed in the second half of 2027.
